Cargando…
A Rabbit Model for the Evaluation of Drugs for Treating the Chronic Phase of Botulism
Antitoxin, the only licensed drug therapy for botulism, neutralizes circulating botulinum neurotoxin (BoNT). However, antitoxin is no longer effective when a critical amount of BoNT has already entered its target nerve cells. The outcome is a chronic phase of botulism that is characterized by prolon...
Autores principales: | Torgeman, Amram, Diamant, Eran, Dor, Eyal, Schwartz, Arieh, Baruchi, Tzadok, Ben David, Alon, Zichel, Ran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537128/ https://www.ncbi.nlm.nih.gov/pubmed/34678971 http://dx.doi.org/10.3390/toxins13100679 |
Ejemplares similares
-
Studying the differential efficacy of postsymptom antitoxin treatment in type A versus type B botulism using a rabbit spirometry model
por: Torgeman, Amram, et al.
Publicado: (2018) -
A Rabbit Model for Prolonged Continuous Intravenous Infusion Via a Peripherally Inserted Central Catheter
por: Dor, Eyal, et al.
Publicado: (2021) -
Small Molecule Receptor Binding Inhibitors with In Vivo Efficacy against Botulinum Neurotoxin Serotypes A and E
por: Ben David, Alon, et al.
Publicado: (2021) -
Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin Drugs
por: Diamant, Eran, et al.
Publicado: (2015) -
Role of Homologous Fc Fragment in the Potency and Efficacy of Anti-Botulinum Antibody Preparations
por: Torgeman, Amram, et al.
Publicado: (2017)